Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
XI’AN, China - Bon Natural Life Limited (NASDAQ:BON), a $5 million market cap company currently trading below its InvestingPro Fair Value, announced Wednesday the launch of its artificial intelligence-driven drug research and development business, aiming to accelerate pharmaceutical discoveries using its extensive library of natural compounds.
The company plans to apply AI algorithms to identify promising lead compounds from its collection of biologically active substances, many derived from Traditional Chinese Medicine (TCM). This approach represents a shift from BON’s previous reliance on traditional screening technologies.
A lead compound is a molecule with specific biological activity that serves as a foundation for further development in drug discovery. BON has accumulated these compounds over nearly two decades of natural product research.
"Backed by the high druggability of our TCM-derived compound libraries and the efficiency of AI-powered screening technology, we are optimistic about Bon’s potential to achieve meaningful breakthroughs in drug discovery," said Yongwei Hu, BON’s CEO, in a press release statement.
The company’s new AI platform is designed to analyze and identify promising lead compounds for optimization, potentially increasing the efficiency and success rate of BON’s drug discovery process.
Bon Natural Life, listed on the Nasdaq, provides bio-ingredient solutions for the natural health and personal care industries. The company is incorporated in the Cayman Islands with operations in China.
In other recent news, Bon Natural Life Limited has made significant strides with several distribution agreements. The company announced a $22 million, 36-month non-exclusive sales distribution agreement with Beijing Huahai Keyuan Technology Co. Ltd. to distribute its natural weight loss product line across China and Southeast Asia. This product line features a "prebiotics + postbiotics" compound formula aimed at weight loss without restrictive dieting. Additionally, Bon Natural Life secured a $16 million, 24-month agreement with the same partner for its prebiotic series products in China.
Furthermore, the company has entered into an $18 million, 36-month agreement with Tianjin Merrill-Youli Trading Co., Ltd. to distribute its Ambroxide and related natural fragrance compounds in the Asia-Pacific region, focusing on the industrial fabric fragrance sector. In another development, Bon Natural Life has regained compliance with Nasdaq’s continued listing requirements, having met the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2). The Nasdaq Hearings Panel has granted the company’s request to maintain its listing on the Nasdaq Capital Market. These recent developments indicate active expansion and compliance efforts by Bon Natural Life.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.